Ryaltris NDC 59467-700

NDC codes

FDA NDC Directory

Product NDC (as listed)59467-700Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59467-0700Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
59467-700-27	59467070027	12 CARTON in 1 BOX (59467-700-27) / 1 BOTTLE, SPRAY in 1 CARTON / 240 SPRAY, METERED in 1 BOTTLE, SPRAYMarketed from Aug 15, 2022
59467-700-84	59467070084	12 CARTON in 1 BOX (59467-700-84) / 1 BOTTLE, SPRAY in 1 CARTON / 56 SPRAY, METERED in 1 BOTTLE, SPRAYMarketed from Aug 15, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ryaltris
Generic name (nonproprietary): olopatadine hydrochloride and mometasone furoate
Active ingredients: Olopatadine hydrochloride — 665 ug/1Mometasone furoate monohydrate — 25 ug/1
Dosage form: Spray, Metered
Route: Nasal
Labeler: HIKMA SPECIALTY USA INC.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 211746
Marketing start: Aug 15, 2022
Listing expires: Dec 31, 2027
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)Corticosteroid Hormone Receptor Agonists (Mechanism)Decreased Histamine Release (Physiologic effect)Histamine H1 Receptor Antagonists (Mechanism)
Identifiers: Product ID 59467-700_84bec5d6-00c3-45a3-ae2b-ec28c8b9a290SPL ID 84bec5d6-00c3-45a3-ae2b-ec28c8b9a290SPL set ID 382eac74-a7ce-4f42-ac0a-b253308f335fRxCUI 2591806, 2591812UNII 2XG66W44KF, MTW0WEG809UPC 0359467700276
Pharmacologic class: Corticosteroid; Histamine-1 Receptor Antagonist; Histamine-1 Receptor Inhibitor; Mast Cell Stabilizer

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Nasal products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459467070027 followed by a unit qualifier and the quantity

Package 59467-0700-27. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 23, 2026.

Indications (excerpt from the label)

RYALTRIS is indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older. RYALTRIS is a combination of olopatadine, a histamine-1 (H1)-receptor inhibitor, and mometasone furoate, a corticosteroid, indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 211746

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 211746
Product	Strength	Form · route	Labeler	Product NDC
Ryaltrisolopatadine hydrochloride and mometasone furoate	Olopatadine hydrochloride 665 ug/1; Mometasone furoate monohydrate 25 ug/1	Spray, MeteredNasal	Glenmark Pharmaceuticals Inc., USA	68462-659